Baxter Q2 revenue rises 5%, beats analyst estimates

Baxter International

30/07/2026 12:26

Overview
US medtech firm's Q2 revenue rose 5%, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 financial outlook

Outlook
Baxter raises full-year 2026 reported sales growth outlook to 3%-4% from flat-1%
Company now expects full-year organic sales growth of 2%-3%, up from approximately flat
Baxter sees full-year adjusted EPS of $1.95-$2.15, up from $1.85-$2.05

Result Drivers
SEGMENT GROWTH - All segments and divisions delivered growth in both the U.S. and internationally, with Medical Products & Therapies and Healthcare Systems & Technologies cited as key contributors
TARIFF REFUND - Adjusted EPS benefited from a $0.11 per share IEEPA tariff refund, which was not previously included in guidance
HIGHER-COST INVENTORY AND COST RECLASSIFICATION - Adjusted EPS was negatively affected by the roll through of higher-cost inventory from late 2025 and an unfavorable comparison due to the reclassification of certain functional costs from SG&A to cost of sales

Company press release: ID:nBw6hbl19a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.96 bln
$2.80 bln (11 Analysts)
Q2 Adjusted EPS
Beat
$0.56
$0.37 (10 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 12 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Baxter International Inc is $21.50, about 13.2% below its July 29 closing price of $24.77
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
July 29 - Boston Scientific trims annual profit forecast on softer Watchman device demand
July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
July 27 - Netherlands' Philips lifts annual profit, cash flow outlook after US tariff refund

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)